JP2022504826A5 - - Google Patents
Info
- Publication number
- JP2022504826A5 JP2022504826A5 JP2021520222A JP2021520222A JP2022504826A5 JP 2022504826 A5 JP2022504826 A5 JP 2022504826A5 JP 2021520222 A JP2021520222 A JP 2021520222A JP 2021520222 A JP2021520222 A JP 2021520222A JP 2022504826 A5 JP2022504826 A5 JP 2022504826A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- chain variable
- variable domain
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744059P | 2018-10-10 | 2018-10-10 | |
| US62/744,059 | 2018-10-10 | ||
| PCT/CA2019/051448 WO2020073131A1 (en) | 2018-10-10 | 2019-10-10 | Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504826A JP2022504826A (ja) | 2022-01-13 |
| JP2022504826A5 true JP2022504826A5 (https=) | 2022-10-18 |
| JP7596263B2 JP7596263B2 (ja) | 2024-12-09 |
Family
ID=70164178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520222A Active JP7596263B2 (ja) | 2018-10-10 | 2019-10-10 | ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230052369A1 (https=) |
| EP (1) | EP3864051A4 (https=) |
| JP (1) | JP7596263B2 (https=) |
| KR (1) | KR20210076918A (https=) |
| CN (2) | CN121758617A (https=) |
| AU (1) | AU2019356806B2 (https=) |
| BR (1) | BR112021006784A2 (https=) |
| CA (1) | CA3113539A1 (https=) |
| MX (1) | MX2021004058A (https=) |
| WO (1) | WO2020073131A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230265202A1 (en) * | 2020-04-15 | 2023-08-24 | Zymeworks Inc. | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof |
| JP7512394B2 (ja) * | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
| AU2022260298A1 (en) * | 2021-04-23 | 2023-11-02 | Shanghai Henlius Biotech, Inc. | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| CN116769041A (zh) * | 2022-03-10 | 2023-09-19 | 合肥瀚科迈博生物技术有限公司 | 靶向msln和4-1bb的双特异性抗体及其应用 |
| WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
| JP2025536308A (ja) * | 2022-10-18 | 2025-11-05 | テューブリス ゲーエムベーハー | 新規なＮａＰｉ２ｂ抗体を有する新規な抗体－薬物コンジュゲート、治療的方法、ならびにそれらの使用 |
| WO2025131027A1 (en) * | 2023-12-21 | 2025-06-26 | Lanova Medicines Development Co., Ltd. | Anti-slc34a2/anti-4-1bb antibodies and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140004174A (ko) * | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP3445788B1 (en) * | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| CN110177805B (zh) * | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| AU2018224094B2 (en) * | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
-
2019
- 2019-10-10 JP JP2021520222A patent/JP7596263B2/ja active Active
- 2019-10-10 WO PCT/CA2019/051448 patent/WO2020073131A1/en not_active Ceased
- 2019-10-10 KR KR1020217011608A patent/KR20210076918A/ko active Pending
- 2019-10-10 AU AU2019356806A patent/AU2019356806B2/en active Active
- 2019-10-10 MX MX2021004058A patent/MX2021004058A/es unknown
- 2019-10-10 EP EP19871359.6A patent/EP3864051A4/en active Pending
- 2019-10-10 CN CN202511697951.3A patent/CN121758617A/zh active Pending
- 2019-10-10 CN CN201980066726.6A patent/CN112996809A/zh active Pending
- 2019-10-10 BR BR112021006784-1A patent/BR112021006784A2/pt unknown
- 2019-10-10 CA CA3113539A patent/CA3113539A1/en active Pending
-
2021
- 2021-04-09 US US17/226,834 patent/US20230052369A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504826A5 (https=) | ||
| CN111518214B (zh) | 靶向cldn18.2的双特异性抗体及其制备方法和应用 | |
| JP2019524693A5 (https=) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2020508655A5 (https=) | ||
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2022545647A5 (https=) | ||
| JP2019520797A5 (https=) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2018537421A5 (https=) | ||
| IL285101B2 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| JP2017504578A5 (https=) | ||
| JP2019502694A5 (https=) | ||
| JP2013515508A5 (https=) | ||
| IL274071B1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| JP2021515798A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| JP6966330B2 (ja) | Ｉｉｉ型分泌装置標的化分子 | |
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP2020515277A5 (https=) |